Identification of neoantigens and immunological subtypes in clear cell renal cell carcinoma for mRNA vaccine development and patient selection

Daoqi Zhu; Jiabin Yang; Minyi Zhang; Zhongxiao Han; Meng Shao; Qin Fan; Yun Ma; Dandan Xie; Wei Xiao

doi:doi:10.18632/aging.204798

← Back

Research Paper Volume 15, Issue 11 pp 5190—5214

Identification of neoantigens and immunological subtypes in clear cell renal cell carcinoma for mRNA vaccine development and patient selection

Figure 5. Cellular characteristics of immune subtypes. (A) Distribution of immune subtypes (ImmuC1-C6) across C1/C2 ccRCC patients. (B) Overall activity of immune cells in C1/C2 ccRCC patients. (C, D) Immune score and stromal score of C1/C2 ccRCC patients from TCGA and ICGC cohorts. (E–H) Tumor purity and CYT score of C1/C2 ccRCC patients from TCGA (E, G) and ICGC (F, H) cohorts. (I, J) Immune cell proportions of C1/C2 ccRCC patients from TCGA and ICGC cohorts separately. ^*padj < 0.05; ^**padj < 0.01; ^***padj < 0.001.